Stimulation of T cells with tumor-specific peptide to develop immunotherapy
2017
University of Tübingen, Tübingen, Germany
The discovery of antigens specific to tumor cells is of crucial importance to develop efficient immunotherapy against cancer. Recent genome sequencing has uncovered a recurring somatic and oncogenic driver mutation of the Toll-like receptor adaptor protein MYD88 with the potential to be a specific antigen used for immunotherapy. Using in silico predictions, the researchers identified different MYD88L265P peptides and tested them for their stimulation capacity on T cells obtained from diseased patients. Cytotoxic capacity after stimulation was tested in vitro. The study shows the potential of stimulation to generate tumor-specific immunotherapy.
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
Alexander N. R. Weber
Added on: 07-29-2021
[1] https://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1219825[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
